My Compounding Pharmacy Expands to Offer Veterinary Services Across Australia 
Celularity Provides Corporate Update
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, has...
Florida Oncology and Hematology and American Oncology Network Opens New Location in Cape Coral, Welcomes Medical Director, Dr. Van den Bergh, and Drs. Venkata Parsa, and Shivtaj Mann
Board-certified medical oncologists Magali Van den Bergh, MD, Venkata Parsa, MD, and Shivtaj Mann, DO join the Cape Coral physician...
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
The Company will Host a Conference Call and Webcast on Thursday, November 7, 2024, at 8:30 AM ETCORAL GABLES, Fla.,...
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
European Patent Office to grant a patent for DRP® companion diagnostic for Allarity’s stenoparib cancer therapy Patent applications for the...
Reflect Scientific Inc. Secures $225,000 Order for Cutting-Edge Freezer Systems
OREM, Utah, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (OTCQB: RSCF), a leading innovator in cryogenic technology, announced...
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9...
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative...
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
XOMA Royalty has acquired 50 percent of Twist’s existing royalty and milestone economics for $15 million XOMA Royalty’s portfolio now...
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS.REC-3964 represents a novel, non-antibiotic approach with a unique mechanism...
Annovis to Highlight Buntanetap’s Alzheimer’s Research Progress with Presentations at CTAD 2024
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"),...
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing...
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute...
MangoRx Announces Formation of Strategy and Alternatives Committee
Dallas, Texas, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing,...
Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure...
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Top-line Data Now Anticipated in Q1 2025 LX9211 has previously received Fast Track designation from the U.S. Food and Drug...
Viemed Healthcare Announces Third Quarter 2024 Earnings Conference Call Details
LAFAYETTE, La., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in...
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton...
ProPhase Labs to Present at the 2024 ThinkEquity Conference
GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next...